Search

Author/Creator Ceresoli, G L

1. 1404PSafety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. (23rd October 2018)

Authors:
Morelli, A M; Migliorino, M R; Morabito, A; Chiari, R; Grossi, F; Bordi, P; Di Costanzo, F; Delmonte, A; Romano, G; Misino, A; Scotti, V; Gregorc, V; Pisconti, S; Ceresoli, G L; Del Conte, A; Colantonio, I; Ciuffreda, L; Capelletto, E; Stura, I; Novello, S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1807PSTELLAR: Final results of a phase II trial of TTFields with chemotherapy for first-line treatment of pleural mesothelioma. (23rd October 2018)

Authors:
Grosso, F; Aerts, J G; Madrzak, J; Dziadziuszko, R; Ramlau, R; Cedres, S; Hiddinga, B; van Meerbeeck, J P; Mencoboni, M; Planchard, D; Chella, A; Crino, L; Krzakowski, M J; Ceresoli, G L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 1818TiPMulticentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM. (23rd October 2018)

Authors:
Pagano, M; Zanelli, F; Gnoni, R; Bonelli, C; Tiseo, M; Boni, L; Ceresoli, G L; Zucali, P A; Grosso, F; Pasello, G; Cappuzzo, F; Pinto, C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 509PSecond-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial. (24th November 2019)

Authors:
Camerini, A; Morabito, A; Montanino, A; Bernabe Caro, R; Grossi, F; Ramlau, R; Ciuleanu, T-E; Ceresoli, G L; Pasello, G; de Marinis, F; Bosch-Barrera, J; Landreau, P; Gautier, S; Ta Thanh Minh, C; Kowalski, D
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. LBA4Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. (17th December 2018)

Authors:
Herbst, R S; Garon, E B; Kim, D-W; Chul Cho, B; Pérez Gracia, J L; Han, J-Y; Dubos Arvis, C; Majem, M; Forster, M; Monnet, I; Novello, S; Szalai, Z; Gubens, M A; Su, W-C; Ceresoli, G L; Samkari, A; Jensen, E; Lubiniecki, G M; Baas, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. LBA63Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). (23rd October 2018)

Authors:
Herbst, R S; Garon, E B; Kim, D-W; Chul Cho, B; Pérez Gracia, J L; Han, J-Y; Dubos Arvis, C; Majem, M; Forster, M; Monnet, I; Novello, S; Szalai, Z; Gubens, M A; Su, W-C; Ceresoli, G L; Samkari, A; Jensen, E; Lubiniecki, G M; Baas, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search